The materials you are responsible for are listed below. I would of course encourage you to browse through the other topics under Drug Therapies, including the 3 drug approvals in 2017 and 2018 (Safinamide/Xadago and two new extended-release formulations of amantadine).
Physiological Basis of Parkinson’s
Drug Therapies
Intro to levodopa |
Why must patients take levodopa so frequently? |
What are the major side effects of levodopa? |
Intro to MAO-B inhibitors |
Intro to dopamine agonists |
Nuplazid for Parkinson’s psychosis |
Droxidopa for orthostatic hypotension |